Importantly, the autologous cells (TALs or PBMCs) contain human T cells that have matured in the patient and are therefore more likely to cause GvHD compared with our CD34+ HSC-engrafted humanized mice where GvHD manifests at much later timepoints (>24 weeks after engraftment; ref. 18). This evidence concerns the gene CD34 and graft versus host disease.